Purkiss Capital Advisors LLC acquired a new position in shares of Danaher Co. (NYSE:DHR – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,000 shares of the conglomerate’s stock, valued at approximately $230,000.
Several other hedge funds and other institutional investors have also bought and sold shares of DHR. FMR LLC boosted its position in shares of Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Danaher by 5.4% during the 4th quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock worth $1,971,609,000 after buying an additional 441,012 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Danaher by 3.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after acquiring an additional 148,251 shares in the last quarter. Fisher Asset Management LLC grew its stake in Danaher by 0.6% in the fourth quarter. Fisher Asset Management LLC now owns 4,578,945 shares of the conglomerate’s stock valued at $1,051,097,000 after acquiring an additional 26,305 shares during the period. Finally, Flossbach Von Storch SE increased its holdings in shares of Danaher by 1.2% in the fourth quarter. Flossbach Von Storch SE now owns 3,710,738 shares of the conglomerate’s stock worth $851,800,000 after acquiring an additional 44,490 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.
Insiders Place Their Bets
In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 11.10% of the company’s stock.
Analysts Set New Price Targets
Danaher Trading Up 1.0 %
Shares of Danaher stock opened at $207.73 on Friday. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average is $224.58 and its 200-day moving average is $244.92. The stock has a market cap of $148.47 billion, a P/E ratio of 39.34, a P/E/G ratio of 2.66 and a beta of 0.83.
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the company earned $2.09 EPS. Equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.32 per share. The ex-dividend date is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is presently 24.24%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- How to Calculate Return on Investment (ROI)
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- How to find penny stocks to invest and trade
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Why is the Ex-Dividend Date Significant to Investors?
- MarketBeat Week in Review – 02/24 – 02/28
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.